rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors
Status:
Unknown status
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is multicenter, open-label, randomized, active-controled, phase IV study of local direct
intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , or combination
with surgery for treatment of advanced oral and maxillofacial malignant tumors.